MedTrace Logo

CAR T Cells in Mesothelin-Expressing Breast Cancer

NCT05623488 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-08-12

No results posted yet for this study

Summary

Phase 1 - Safety and Proof of Concept

Conditions

Interventions

DRUG

huCART-meso cells

Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains

DEVICE

Mesothelin Expression Testing

Laboratory Developed Test

Sponsors & Collaborators

Principal Investigators

  • Julia Tchou, MD, PhD · University of Pennsylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-06
Primary Completion
2025-04-07
Completion
2025-04-07
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05623488 on ClinicalTrials.gov